Skip to main navigation Skip to search Skip to main content

Estrogen Receptor α (ERα)-targeting Compounds and Derivatives: Recent Advances in Structural Modification and Bioactivity

  • Wei Yun Guo
  • , Shang Ming Zhu Zeng
  • , Girdhar Singh Deora
  • , Qing Shan Li
  • , Ban Feng Ruan

Research output: Contribution to journal › Article › Research › peer-review

Abstract

Breast cancer is the most common cancer suffered by female, and the second highest cause of cancer-related death among women worldwide. At present, hormone therapy is still the main treatment route and can be divided into three main categories: selective estrogen receptor modulators (SERMs), selective estrogen receptor downregulators (SERDs), and aromatase inhibitors (AIs). However, breast cancer is difficult to cure even after several rounds of anti-estrogen therapy and most drugs have serious side-effects. Here, we review the literature published over the past five years regarding the isolation and synthesis of analogs and their derivatives.

Original languageEnglish
Pages (from-to)1318-1337
Number of pages20
JournalCurrent Topics in Medicinal Chemistry
Volume19
Issue number15
DOIs
Publication statusPublished - 1 Jan 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Analogs
  • Bioactivity
  • Breast cancer
  • Derivatives
  • Estrogen receptor α
  • Structure-activity relationship.

Cite this